What is the recommended acute and chronic management of supraventricular tachycardia (SVT) in hemodynamically stable and unstable patients?

SVT Management

For hemodynamically stable SVT, start with vagal maneuvers (particularly modified Valsalva in supine position), immediately followed by IV adenosine if unsuccessful; for hemodynamically unstable patients, proceed directly to synchronized cardioversion. 1

Acute Management Algorithm

Hemodynamically Stable Patients

First-line interventions:

• Vagal maneuvers (Class I recommendation): Perform with patient supine 1
  • Modified Valsalva: Bear down against closed glottis for 10-30 seconds (30-40 mm Hg pressure)
  • Carotid sinus massage: 5-10 seconds of steady pressure after confirming no bruit
  • Ice-cold wet towel to face (diving reflex)
  • Success rate: 27.7% when switching between techniques 1
  • Never apply pressure to eyeballs - this is dangerous and abandoned 1

Second-line pharmacotherapy:

• Adenosine (Class I recommendation): 90-95% effective for AVNRT/AVRT termination 1, 2
  • Brief side effects (<1 min) in ~30% of patients
  • Critical caveat: Have cardioversion ready - adenosine can precipitate AF with rapid ventricular conduction, potentially causing ventricular fibrillation 1
  • Serves dual diagnostic and therapeutic role 1

Third-line options (if adenosine fails):

• IV calcium channel blockers (diltiazem or verapamil): 64-98% conversion rate 1
  • Contraindications to recognize: Do NOT use if VT, pre-excited AF, or systolic heart failure suspected 1
  • Risk of hemodynamic collapse or ventricular fibrillation in wrong rhythm 1
• IV beta-blockers: Reasonable alternative with excellent safety profile, though less effective than calcium channel blockers 1, 2

Last resort before cardioversion:

• IV amiodarone may be considered when other therapies fail or are contraindicated 1

Hemodynamically Unstable Patients

Immediate synchronized cardioversion (Class I recommendation) 1

• Hemodynamic instability defined as: hypotension, altered mental status, shock, chest pain, acute heart failure 1
• Exception: If narrow-QRS regular tachycardia, adenosine may be attempted first even in unstable patients per some protocols 1, 3
• Recent 2025 data suggests adenosine may be safe first-line attempt in unstable SVT before cardioversion (weighted OR 2.41 for ECV success, but adenosine avoids sedation risks) 3

Special Consideration: Pre-excited AF (Wide-Complex Irregular)

Critical distinction - this is NOT typical SVT management:

• Unstable: Immediate synchronized cardioversion 1
• Stable: IV procainamide or ibutilide (Class I) 1
• NEVER use AV nodal blockers (adenosine, calcium channel blockers, beta-blockers, digoxin) - these can enhance accessory pathway conduction and precipitate ventricular fibrillation 1

Chronic/Ongoing Management

Definitive therapy:

• Catheter ablation is first-line for recurrent symptomatic SVT 4, 5, 6
  • Success rates: 94.3-98.5% for single procedure 4
  • AVNRT ablation: Very low AV block risk, should be offered for symptomatic recurrence 7
  • Preferred over long-term pharmacotherapy per 2019 ESC guidelines 8, 7

Pharmacologic suppression (for patients declining/not candidates for ablation):

• Oral calcium channel blockers (verapamil or diltiazem): Class I recommendation 1
  • Avoid in systolic heart failure 1
  • Monitor for bradyarrhythmias and hypotension 1
• Oral beta-blockers: Alternative or combination therapy 1
• Antiarrhythmic drugs downgraded in recent guidelines - less preferred 8

Critical Pitfalls to Avoid

1. Misdiagnosis as VT: ECG diagnostic accuracy is ~90%, but dangerous misdiagnosis occurs in <2% 3. When in doubt, treat as VT (avoid AV nodal blockers)

2. Calcium channel blocker/beta-blocker in wrong rhythm: Can cause cardiovascular collapse in VT or pre-excited AF 1

3. Post-conversion arrhythmias: Expect atrial/ventricular premature complexes after adenosine or cardioversion that may reinitiate SVT - have antiarrhythmic ready 1

4. Pregnancy considerations: Avoid antiarrhythmic medications especially first trimester; use fluoroscopy-free ablation if needed 7

5. Recurrence after ablation: Higher in post-surgical/congenital heart disease patients; requires specialized center management 9, 10

Strength of Evidence

The 2015 ACC/AHA/HRS guidelines [1-2] provide the definitive framework, with 2019 ESC guidelines 8 upgrading ablation and downgrading many antiarrhythmics. The most recent high-quality evidence from 2024-2025 4, 3 confirms adenosine's safety even in unstable patients and ablation's superior long-term outcomes. The algorithmic approach is consistent across all major guidelines with minor regional variations (European guidelines favor immediate cardioversion for unstable patients, while American guidelines allow adenosine trial first).